Sermorelin + Epitalon Stack: Safety and Monitoring Guide

What each peptide is

Sermorelin is a 29-amino-acid analogue of human growth hormone-releasing hormone (GHRH) and the shortest synthetic peptide with the full biological activity of GHRH [4]. It acts on the pituitary's GHRH receptor to make the body release its own growth hormone; it is not growth hormone itself [4]. After an intravenous dose in healthy men, sermorelin was cleared quickly, but growth hormone stayed raised for about 3 hours [7].

Epitalon (also spelled epithalon) is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, with a molecular weight of about 390 g/mol as the free base. It is distinct from epithalamin, a polypeptide extract from the animal pineal gland: FDA treats epitalon and epithalamin as different substances, so epithalamin studies are not epitalon studies [1]. FDA says epitalon first appears to have been synthesized in 1999 [1].

What the studies actually tested

FDA's July 2026 review found three human studies of epitalon: two sublingual studies in night-shift workers and one eye-injection study in retinitis pigmentosa [1]. Sermorelin's main human data come from children with growth hormone deficiency [3] and a short physiology study in older men [8].

What the sermorelin record shows

Sermorelin acetate was approved as Geref for two uses only: treating idiopathic growth hormone deficiency in children with growth failure, and testing the pituitary's ability to secrete growth hormone [2]. The maker discontinued Geref in 2008 and FDA withdrew both approvals effective June 18, 2009; in March 2013 FDA determined the drug was not withdrawn for reasons of safety or effectiveness [2]. Geref was never approved for adults, anti-aging, weight loss or athletic performance [2].

The main human safety data come from a one-year, open-label, multicenter trial: 110 previously untreated prepubertal children received 30 micrograms per kg subcutaneously at bedtime, and 86 were evaluable for efficacy [3]. No adverse changes were seen in general biochemical or hormonal tests, fasting glucose did not change, IGF-I was not excessively raised, and the drug was well tolerated overall [3].

A separate study gave 10 healthy older men (mean age 68) 0.5 mg or 1 mg subcutaneously twice daily for 14 days each, and compared them with 9 young men (mean age 26). At the higher dose, 24-hour growth hormone and IGF-I rose to levels not significantly different from the young men [8]. That was a short physiology study, not a trial of clinical outcomes, and it provides no long-term safety data.

There is no current approved sermorelin dose because no sermorelin product is FDA-approved today [2]. The 30 micrograms/kg bedtime dose and the 0.5 to 1 mg twice-daily dose are what those studies used; they are not recommendations.

What the epitalon record shows

Epitalon is not an FDA-approved drug and is not a component of one. FDA's July 2026 review found no USP or National Formulary monograph, no listing in the European or Japanese pharmacopeias, and no approved product in the ten countries it checked or authorized by the European Medicines Agency [1].

FDA found no clinical study that assessed epitalon's safety, and no pharmacokinetic data. Its search of the adverse-event database through December 8, 2025 returned no epitalon reports [1].

One placebo-controlled study, as described by FDA, enrolled 75 healthy women aged 40 to 50, mostly night-shift workers; 40 with low melatonin output were split into two groups of 20 and given a sublingual spray delivering about 0.5 mg per day, or placebo, for 20 days. Urinary 6-sulfatoxymelatonin rose about 1.7-fold with epitalon and did not change with placebo, and 83% versus 25% were described as improved in mood and physical condition, but no sleep outcomes were measured, blinding was not specified, and the study was short and small [1].

An older controlled study injected epitalon beside the eye in people with degenerative retinal lesions and reported a positive clinical effect in 90% of cases, without reporting sample sizes or design details in the abstract [9]. A 2026 narrative review concluded that epitalon is biologically active but clinically unproven, with inadequate pharmacokinetic, dose-ranging and long-term safety data [10].

The cancer question

In cultured human fetal fibroblasts that lack telomerase, epitalon induced telomerase activity and telomere elongation [5]. That is a cell-culture result. FDA warned that because epitalon activates telomerase and lengthens telomeres, and longer telomeres are generally linked to higher cancer risk, the peptide has a mechanistic potential to be carcinogenic [1].

In one mouse study, female HER-2/neu transgenic mice given 1 microgram of epitalon per mouse for 5 consecutive days each month developed fewer and smaller mammary tumors than saline-treated mice [11]. FDA found the mouse studies of cancer and chromosome damage too limited to show safety (one fixed dose, female mice only, short exposure) [1].

What can actually be monitored

In the sermorelin studies, IGF-I and fasting glucose were the safety-related measures reported. IGF-I rose with 1 mg twice daily in the 14-day study of older men [8]; in the pediatric trial it was not excessively raised and fasting glucose did not change [3].

For epitalon, FDA found no pharmacokinetic data and no clinical safety study [1], and the 2026 narrative review found its dose-ranging and long-term safety data inadequate [10].

Regulatory status

With Geref withdrawn, sermorelin sold in the US today is compounded, and compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before marketing [12][2]. Sermorelin does not appear in any category on FDA's list for state-licensed pharmacies and physicians, and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [13][14].

For epitalon, FDA staff proposed in July 2026 that neither the free base nor the acetate be added to the compounding bulks list, evaluating only the insomnia use; the reasons included that epitalon is not well characterized, raises an immunogenicity concern for subcutaneous injection, and has no clinical safety data [1]. The Pharmacy Compounding Advisory Committee voted on July 24, 2026 in favor of adding it, against staff advice. That vote is advice only, it is not binding, and epitalon is not on the list [15][12].

HHS's draft enforcement-discretion policy, filed October 28, 2026, names epitalon among six peptides and covers epitalon acetate given by subcutaneous or intramuscular injection in intermittent courses. HHS says it does not intend to take enforcement action against certain state-licensed pharmacies, federal facilities or licensed physicians if conditions are met, such as a patient-specific prescription and a manufacturer certificate of analysis. The notice says the policy is not binding, creates no rights, and is not an approval [12][14].

Sport

Sermorelin is named in WADA's 2026 Prohibited List under S2.2.4 (growth hormone releasing factors) and is prohibited at all times, in and out of competition; it is named again in the 2027 list [6][16]. Epitalon is not named on either list. Class S0 prohibits any substance with no current approval by a governmental regulatory health authority for human therapeutic use and gives BPC-157 as one example, and there is no WADA statement on whether epitalon falls under S0 [6][16].